Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Diabetes Mellitus, Type 2 · Pharmacokinetic trial

Boehringer Ingelheim

Boehringer Ingelheim clinical programs — 62 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Binger Straße, Ingelheim am Rhein, Rhineland-Palatinate 55218, DE HQ
46,699 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Binger Straße, Ingelheim am Rhein, Rhineland-Palatinate 55218, DE
Employees
46,699
Programs
193
Drugs
113
Patents
25
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

Boehringer Ingelheim projects

62 ClinicalTrials.gov programs sponsored by Boehringer Ingelheim.

Boehringer Ingelheim has 62 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

62 programs

Clinical programs

Page 1 of 2

  1. 1199-0378

    Boehringer Ingelheim

    Childhood Interstitial Lung Disease

    phase 3 small molecule active

    1 trial

  2. 1245-0256

    Boehringer Ingelheim

    Chronic kidney disease in paediatric patients

    phase 3 small molecule active

    1 trial

  3. 1305-0023

    Boehringer Ingelheim

    Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

    phase 3 small molecule active

    1 trial

  4. 1305-0046

    Boehringer Ingelheim

    Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD)

    phase 3 small molecule active

    1 trial

  5. 1305-0069

    Boehringer Ingelheim

    Interstitial lung diseases, Familial pulmonary fibrosis, Pulmonary fibrosis

    phase 3 small molecule active

    1 trial

  6. 1346-0014

    Boehringer Ingelheim

    Schizophrenia

    phase 3 other active

    1 trial

  7. 1378-0018

    Boehringer Ingelheim

    Heart failure

    phase 3 small molecule active

    1 trial

  8. 1378-0020

    Boehringer Ingelheim

    Heart failure (HF)

    phase 3 small molecule active

    1 trial

  9. 1378-0041

    Boehringer Ingelheim

    Type 2 diabetes, hypertension, cardiovascular disease

    phase 3 small molecule active

    1 trial

  10. 1403-0008

    Boehringer Ingelheim

    Advanced dedifferentiated liposarcoma

    phase 3 small molecule active

    1 trial

  11. 1403-0019

    Boehringer Ingelheim

    dedifferentiated liposarcoma

    phase 3 small molecule active

    1 trial

  12. 1404-0038

    Boehringer Ingelheim

    Obesity

    phase 3 small molecule active

    1 trial

  13. 1404-0040

    Boehringer Ingelheim

    Obesity

    phase 3 small molecule active

    1 trial

  14. 1404-0041

    Boehringer Ingelheim

    Obesity, Diabetes mellitus type II

    phase 3 small molecule active

    1 trial

  15. 1404-0056

    Boehringer Ingelheim

    Obesity

    phase 3 small molecule active

    1 trial

  16. 1438-0011

    Boehringer Ingelheim

    advanced or metastatic extrapulmonary neuroendocrine carcinoma

    phase 3 small molecule active

    1 trial

  17. 1438-0012

    Boehringer Ingelheim

    small cell lung cancer

    phase 3 small molecule active

    1 trial

  18. 1479-0008

    Boehringer Ingelheim

    non-squamous non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  19. 1479-0032

    Boehringer Ingelheim

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  20. Afatinib

    Boehringer Ingelheim

    Head and Neck Neoplasms

    phase 3 small molecule completed

    1 trial

  21. BI 1015550, BI 1015550

    Boehringer Ingelheim

    idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF)

    phase 3 small molecule active

    1 trial

  22. BI 10773

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  23. BI 1291583

    Boehringer Ingelheim

    Bronchiectasis

    phase 3 small molecule active

    1 trial

  24. BI 201335

    Boehringer Ingelheim

    Hepatitis C

    phase 3 small molecule completed

    1 trial

  25. BI 201335

    Boehringer Ingelheim

    Hepatitis C, Chronic

    phase 3 small molecule completed

    1 trial

  26. BI 695501

    Boehringer Ingelheim

    Arthritis, Rheumatoid

    phase 3 small molecule completed

    2 trials

  27. BI 764198

    Boehringer Ingelheim

    Focal Segmental Glomerulosclerosis

    phase 3 small molecule active

    1 trial

  28. BI 764198, Placebo matching BI 764198

    Boehringer Ingelheim

    Focal segmental glomerulosclerosis

    phase 3 small molecule active

    1 trial

  29. Brigimadlin

    Boehringer Ingelheim

    Liposarcoma, Dedifferentiated

    phase 3 small molecule completed

    1 trial

  30. Empagliflozin

    Boehringer Ingelheim

    Heart Failure

    phase 3 small molecule completed

    1 trial

  31. Empagliflozin

    Boehringer Ingelheim

    Chronic Kidney Disease

    phase 3 small molecule active

    1 trial

  32. Empagliflozin

    Boehringer Ingelheim

    Myocardial Infarction

    phase 3 small molecule completed

    1 trial

  33. Iclepertin

    Boehringer Ingelheim

    Schizophrenia

    phase 3 small molecule terminated

    2 trials

  34. Linagliptin

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    3 trials

  35. Metalyse 5 000 units (25 mg) powder for solution for injection

    Boehringer Ingelheim

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial

  36. Nintedanib

    Boehringer Ingelheim

    Lung Diseases, Interstitial

    phase 3 small molecule completed

    1 trial

  37. Nintedanib

    Boehringer Ingelheim

    Idiopathic Pulmonary Fibrosis

    phase 3 small molecule completed

    1 trial

  38. Olodaterol (BI 1744)

    Boehringer Ingelheim

    Pulmonary Disease, Chronic Obstructive

    phase 3 small molecule completed

    2 trials

  39. Pemetrexed

    Boehringer Ingelheim

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

  40. Placebo

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    3 trials

  41. Placebo matching BI 1291583, BI 1291583

    Boehringer Ingelheim

    Bronchiectasis

    phase 3 small molecule active

    1 trial

  42. Placebo matching to spesolimab

    Boehringer Ingelheim

    Pyoderma gangrenosum

    phase 3 small molecule active

    1 trial

  43. Pramipexol Extended Release

    Boehringer Ingelheim

    Early Parkinson Disease (Early PD)

    phase 3 small molecule completed

    1 trial

  44. Spesolimab - solution for infusion

    Boehringer Ingelheim

    Netherton Syndrome

    phase 3 small molecule terminated

    1 trial

  45. Spesolimab i.v.

    Boehringer Ingelheim

    Hidradenitis Suppurativa

    phase 3 small molecule completed

    1 trial

  46. Spesolimab, Placebo matching to Spesolimab

    Boehringer Ingelheim

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule active

    1 trial

  47. Warfarin

    Boehringer Ingelheim

    Thromboembolism

    phase 3 small molecule completed

    1 trial

  48. dabigatran dose 1

    Boehringer Ingelheim

    Atrial Fibrillation

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Boehringer Ingelheim have?

62 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.